Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

Tuberculosis Clinical Trial

Official title:

Safety, Reactogenicity & Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Administered Intramuscularly According to a Schedule of 0, 1 Month, to Healthy Adults Aged 18 to 50 Years

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00397943
• Other study ID #: 106227
• Secondary ID: 1062281087361087
• Status: Completed
• Phase: Phase 2
• Start date: November 15, 2006
• Est. completion date: December 1, 2009

Study information

• Verified date: June 2019
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the safety and immunogenicity of 2 different formulations of tuberculosis vaccine GSK692342 in healthy adults.

Description:

The study is designed to have a vaccination phase (includes screening, 2 doses of vaccine 1 month apart and follow-up until 1 month post dose 2), which will be performed in an observer blinded manner. This will be followed by 3 years of follow-up which will continue in an open manner.

No new subjects will be recruited at the follow-up phase. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: December 1, 2009
• Est. primary completion date: December 1, 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Subjects who the investigator believes that they can and will comply with the requirements of the protocol

• A male or female between, and including, 18 and 50 years of age at the time of the first vaccination.

• Written informed consent obtained from the subject prior to any study procedure.

• Free of obvious health problems as established by medical history and clinical examination before entering into the study.

• Subjects must have PPD negative skin reactivity (0 mm induration 48 to 72 hours after PPD skin test administration).

• Clinically normal laboratory values for creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), complete blood count (CBC) and differential, haemoglobin, platelet count and urinalysis.

• Seronegative for human immunodeficiency virus-1 and 2 (HIV 1/2) antibodies, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibodies

• If the subject is female, she must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.

• No evidence of pulmonary pathology (i.e. acute or chronic pulmonary disease; past TB infection/disease) as confirmed by chest X-ray.

Exclusion Criteria:

• History of previous exposure to experimental products containing components of the experimental vaccine.

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.

• Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose.

• Any chronic drug therapy to be continued during the study period. Vitamins and/or dietary supplements, herbal medications, birth control pills, anti-histamines for seasonal allergies, SSRIs (e.g. Prozac, Zoloft, Paxil), NSAIDs (nonsteroidal anti-inflammatory drugs e.g. aspirin, ibuprofen), and acetaminophen are allowed.

• History of documented exposure to Mycobacterium tuberculosis.

• History of prior vaccination with experimental Mycobacterium tuberculosis vaccines.

• Administration of any immunoglobulins, any immunotherapy and/or any blood products within the 3 months preceding the first dose of study vaccination, or planned administrations during the study period.

• Participation in another experimental protocol during the study period.

• Any confirmed or suspected immunosuppressive or immunodeficient condition; or family history of congenital or hereditary immunodeficiency.

• History of hypersensitivity to vaccines or vaccine components

• History of any acute or chronic illness or medication that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.

• Volunteers with a personal history of autoimmune disease or who describe a first-degree relative with clearly documented autoimmune disease.

• History of any neurological disorders or seizures.

• History of chronic alcohol consumption and/or drug abuse.

• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.

• Major congenital defects.

• Pregnant female, lactating female or female planning to become pregnant or planning to discontinue contraceptive precautions.

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Biological:
• GSK's candidate Mycobacterium tuberculosis vaccine 692342
Intramuscular injection, 2 doses at 0, 1 month
• Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system
Intramuscular injection, 2 doses at 0, 1 month
• Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline
Intramuscular injection, 2 doses at 0, 1 month
• Control vaccine with the adjuvant system.
Intramuscular injection, 2 doses at 0, 1 month

Locations

Country	Name	City	State
Belgium	GSK Investigational Site	Gent

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitié MA, Mettens P, Moris P, Ledent E, Leroux-Roels G, Ofori-Anyinam O; M72 Study Group. Improved CD4? T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine. 2013 Apr 19;31(17):2196-206. doi: 10.1016/j.vaccine.2012.05.035. Epub 2012 May 27. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.	During the 7-day (Days 0-6) follow-up period after each vaccine dose and across doses
Primary	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above (=) 37.5 degrees Celsius (°C)], gastrointestinal symptoms and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as causally related to the study vaccination.	During the 7-day (Days 0-6) follow-up period after each vaccine dose and across doses
Primary	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.	During the 30-day (Days 0-29) follow-up period after each vaccine dose
Primary	Number of Subjects With Serious Adverse Events (SAEs)	SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	During the Active Vaccination Phase (from Day 0 up to Month 2)
Primary	Number of Subjects With SAEs	SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	From Month 2 up to Month 12
Primary	Number of Subjects With SAEs	SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Note: Follow-up during Year 2 continued only for the M72/AS01B Group and M72/AS02A Group.	From Month 12 up to Month 24
Primary	Number of Subjects With SAEs	SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Note: Follow-up during Year 3 continued only for the M72/AS01B Group and M72/AS02A Group.	From Month 24 up to Month 36
Primary	Number of Subjects With Normal or Abnormal Haematological and Biochemical Levels	Among haematological and biochemical parameters assessed were Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Basophils, Creatinine, Eosinophils, Haemoglobin, Haematocrite, Lymphocytes, Monocytes, Neutrophils, Platelets, Red blood cells (RBC), White blood cells (WBC). Inside = within laboratory reference range; Above = above laboratory reference range; Below = below laboratory reference range.	At Day 0
Primary	Number of Subjects With Normal and Abnormal Haematological and Biochemical Levels	Among haematological and biochemical parameters assessed were Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Basophils, Creatinine, Eosinophils, Haemoglobin, Haematocrite, Lymphocytes, Monocytes, Neutrophils, Platelets, Red blood cells (RBC), White blood cells (WBC). Inside = within laboratory reference range; Above = above laboratory reference range; Below = below laboratory reference range.	At Day 7
Primary	Number of Subjects With Normal or Abnormal Haematological and Biochemical Levels	Among haematological and biochemical parameters assessed were Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Basophils, Creatinine, Eosinophils, Haemoglobin, Haematocrite, Lymphocytes, Monocytes, Neutrophils, Platelets, Red blood cells (RBC), White blood cells (WBC). Inside = within laboratory reference range; Above = above laboratory reference range; Below = below laboratory reference range.	At Day 30
Primary	Number of Subjects With Normal or Abnormal Haematological and Biochemical Levels	Among haematological and biochemical parameters assessed were Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Basophils, Creatinine, Eosinophils, Haemoglobin, Haematocrite, Lymphocytes, Monocytes, Neutrophils, Platelets, Red blood cells (RBC), White blood cells (WBC). Inside = within laboratory reference range; Above = above laboratory reference range; Below = below laboratory reference range.	At Day 37
Primary	Number of Subjects With Normal or Abnormal Haematological and Biochemical Levels	Among haematological and biochemical parameters assessed were Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Basophils, Creatinine, Eosinophils, Haemoglobin, Haematocrite, Lymphocytes, Monocytes, Neutrophils, Platelets, Red blood cells (RBC), White blood cells (WBC). Inside = within laboratory reference range; Above = above laboratory reference range; Below = below laboratory reference range.	At Day 60
Primary	Levels of C-reactive Protein	The levels of C-reactive protein are expressed in milligram per deciliter (mg/dL).	At Day 0
Primary	Levels of C-reactive Protein	The levels of C-reactive protein are expressed in milligram per deciliter (mg/dL).	At Day 1
Primary	Levels of C-reactive Protein	The levels of C-reactive protein are expressed in milligram per deciliter (mg/dL).	At Day 7
Primary	Levels of C-reactive Protein	The levels of C-reactive protein are expressed in milligram per deciliter (mg/dL).	At Day 30
Primary	Levels of C-reactive Protein	The levels of C-reactive protein are expressed in milligram per deciliter (mg/dL).	At Day 31
Primary	Levels of C-reactive Protein	The levels of C-reactive protein are expressed in milligram per deciliter (mg/dL).	At Day 37
Primary	Levels of Immunoglobulin E	The levels of Immunoglobulin E are expressed in 1000 units per liter (1000 U/L).	At Day 0
Primary	Levels of Immunoglobulin E	The levels of Immunoglobulin E are expressed in 1000 units per liter (1000 U/L).	At Day 1
Primary	Levels of Immunoglobulin E	The levels of Immunoglobulin E are expressed in 1000 units per liter (1000 U/L).	At Day 7
Primary	Levels of Immunoglobulin E	The levels of Immunoglobulin E are expressed in 1000 units per liter (1000 U/L).	At Day 30
Primary	Levels of Immunoglobulin E	The levels of Immunoglobulin E are expressed in 1000 units per liter (1000 U/L).	At Day 31
Primary	Levels of Immunoglobulin E	The levels of Immunoglobulin E are expressed in 1000 units per liter (1000 U/L).	At Day 37
Secondary	Antibody Concentrations Against Mycobacterium Tuberculosis (M. Tuberculosis) Fusion Proteins M72 and Mtb72F	Antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EU/mL). The reference seropositivity cut-off values for anti-M72 and anti-Mtb72F antibodies were = 2.8 EU/mL and = 1.0 EU/mL, respectively.	At Day 0, prior to Dose 2 (Month 1), 1 month post-Dose 2 (Month 2) and Year 1 (Month 12)
Secondary	Antibody Concentrations Against M. Tuberculosis Fusion Protein M72	Antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EU/mL). The reference seropositivity cut-off value for anti-M72 antibodies was = 2.8 EU/mL.	At Year 2 (Month 24) and Year 3 (Month 36)
Secondary	Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4/8 (CD4/CD8+) T-cells Expressing at Least Two Different Cytokines	Among cytokines expressed were interleukin-2 [IL-2] and/or interferon-gamma [IFN-?] and/or tumour necrosis factor-alpha [TNF-a] and/or cluster of differentiation 40-ligand [CD40-L]. The analysis of cytokines expression was performed by flow cytometry using intracellular cytokine staining (ICS) on frozen peripheral blood mononuclear cell (PBMCs). Note: No vaccine induced responses were observed for CD8+ T-cells, so no results are presented throughout the record.	At Day 0, prior to Dose 2 (Month 1), 1 month post-Dose 2 (Month 2) and Year 1 (Month 12)
Secondary	Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Different Cytokines	Among cytokines expressed were interleukin-2 [IL-2] and/or interferon-gamma [IFN-?] and/or tumour necrosis factor-alpha [TNF-a] and/or cluster of differentiation 40-ligand [CD40-L]. The analysis of cytokines expression was performed by flow cytometry using intracellular cytokine staining (ICS) on frozen peripheral blood mononuclear cell (PBMCs).	At Year 2 (Month 24) and Year 3 (Month 36)
Secondary	Frequency of M72 Specific CD4+ T-cells Expressing at Least One Cytokine and Another Signal Molecule	Expressed cytokine combinations for CD4+ T-cells were CD40-L and interleukin-2 [IL-2] or interferon-gamma [IFN-?] or tumour necrosis factor-alpha [TNF-a]; IL-2 and CD40-L, or IFN-?, or TNF-a; IFN-? and CD40-L, or IL-2, or TNF-a; TNF-a and CD40-L, or IL-2, or IFN-?.	At Day 0, prior to Dose 2 (Month 1), 1 month post-Dose 2 (Month 2) and Year 1 (Month 12)
Secondary	Frequency of M72 Specific CD4+ T-cells Expressing at Least One Cytokine and Another Signal Molecule	Expressed cytokine combinations for CD4+ T cells were CD40-L and interleukin-2 [IL-2] or interferon-gamma [IFN-?] or tumour necrosis factor-alpha [TNF-a]; IL-2 and CD40-L, or IFN-?, or TNF-a; IFN-? and CD40-L, or IL-2, or TNF-a; TNF-a and CD40-L, or IL-2, or IFN-?.	At Year 2 (Month 24) and Year 3 (Month 36)
Secondary	Number of Subjects With Response to M72-specific CD4+ T-cells Secreting at Least Two Different Cytokines/Activation Markers	The cut-off value used for analysis of the frequency of cells expressing cytokines/immune markers was the 313 CD4+ T-cells per million CD4+ T-cells, i.e. the 95th percentile of the pre-vaccination level of cells expressing cytokines/immune markers.	At Day 0, prior to Dose 2 (Month 1), 1 month post-Dose 2 (Month 2) and Year 1 (Month 12)
Secondary	Number of Subjects With Response to M72-specific CD4+ T-cells Secreting at Least Two Different Cytokines/Activation Markers	The cut-off value used for analysis of the frequency of cells expressing cytokines/immune markers was the 313 CD4+ T-cells per million CD4+ T-cells, i.e. the 95th percentile of the pre-vaccination level of cells expressing cytokines/immune markers.	At Year 2 (Month 24) and Year 3 (Month 36)
Secondary	Concentrations of IFN-? Produced in Serum Samples	Concentrations are presented as geometric mean concentrations (GMCs), expressed in picogram per milliliter (pg/mL). The reference seropositivity cut-off value was equal to or above (=) 1 pg/mL.	Prior to (Day 0 and Day 30) and one day (Day 1 and Day 31) after each vaccination